Ischemia Care
Private Company
Funding information not available
Overview
Ischemia Care is a private, commercial-stage diagnostics company founded in 2017 and headquartered in San Francisco, CA. It has pioneered a blood-based RNA expression test (ISCDx) to determine the cause of ischemic stroke, addressing the significant clinical challenge of cryptogenic (unknown cause) strokes. The company's platform is supported by data from the large, prospective BASE clinical trial (NCT02014896), which enrolled 1,700 patients. Ischemia Care aims to integrate its testing into clinical workflows to enable precision secondary stroke prevention and reduce healthcare costs.
Technology Platform
Blood-based diagnostic platform using RNA expression analysis (transcriptomics) and artificial intelligence to determine stroke etiology and related conditions.
Opportunities
Risk Factors
Competitive Landscape
Ischemia Care positions itself as the first and only company with a commercially available RNA-based test for stroke etiology. Competition exists from companies researching protein biomarkers (e.g., Banyan Biomarkers' CTE blood test had a stroke indication) and extensive academic research into multi-omics biomarkers for stroke, but no direct, widely adopted commercial competitor is currently evident in the stroke etiology sub-field.